CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
effectiveness of the NanoKnife System when used to ablate localized prostate cancer in intermediate risk subjects with organ-confin ...
Rochester, Minnesota, United States and 1 other location
of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate...
Phase 2
Rochester, Minnesota, United States and 16 other locations
This study evaluates the diagnostic performance and safety of [18F]PSMA-1007 PET/CT imaging in patients with suspected recurrence of prostate...
Phase 3
Rochester, Minnesota, United States and 5 other locations
of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate...
Rochester, Minnesota, United States and 29 other locations
This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men with metastatic castration resistant prostate ca...
Phase 2
Rochester, Minnesota, United States and 17 other locations
The purpose of this study is to establish the maximum tolerable dose of niraparib when combined with prostate stereotactic body radiotherapy...
Phase 1, Phase 2
Rochester, Minnesota, United States and 5 other locations
hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with on ...
Phase 3
Rochester, Minnesota, United States and 272 other locations
prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate...
Phase 3
Rochester, Minnesota, United States and 538 other locations
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA...
Phase 3
Rochester, Minnesota, United States and 394 other locations
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned t...
Phase 3
Rochester, Minnesota, United States and 559 other locations
Clinical trials
Research sites
Resources
Legal